Effect of Fedratinib Versus Best Available Therapy on Patient-Reported Outcomes in Patients with Myelofibrosis Who Were Previously Treated with Ruxolitinib: Results from the Phase 3 FREEDOM2 Trial

被引：0
|
作者：
Harrison, Claire [1 ]
Lord-Bessen, Jennifer [2 ]
Shi, Ling [3 ]
Guo, Shien [3 ]
Yucel, Aylin [2 ]
Zissler, Dorothy [2 ]
Jones, Shalon [2 ]
Slaff, Samantha [2 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, London, England
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Evidera, Bethesda, MD USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-198368
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6624 / 6625
页数：2
相关论文
共 50 条
  • [21] Canakinumab Improves Patient-Reported Outcomes in Patients with Recurrent Fever Syndromes: Results from a Phase 3 Trial
    Lachmann, Helen
    Lauwerys, Bernard
    Miettunen, Paivi
    Kallinich, Tilmann
    Jansson, Annette
    Rosner, Itzhak
    Manna, Raffaele
    Murias, Saramaria
    Savic, Sinisa
    Smeets, Serge
    De Benedetti, Fabrizio
    Simon, Anna
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [22] Effect of Tofacitinib on Patient-Reported Outcomes in Patients with Active Psoriatic Arthritis: Results from 2 Phase 3 Studies
    Strand, Vibeke
    de Vlam, Kurt
    Covarrubias-Cobos, Jose A.
    Mease, Philip J.
    Gladman, Dafna D.
    Hendrikx, Thijs
    Kudlacz, Elizabeth
    Graham, Daniela
    Wu, Joseph
    Cappelleri, Joseph C.
    Hsu, Ming-Ann
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [23] Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2
    Ostor, Andrew J. K.
    Soliman, Ahmed M.
    Papp, Kim A.
    Padilla, Byron
    Wang, Zailong
    Eldred, Ann
    de Vlam, Kurt
    Kivitz, Alan
    RMD OPEN, 2022, 8 (02):
  • [24] CANAKINUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH RECURRENT FEVER SYNDROMES: RESULTS FROM A PHASE 3 TRIAL (CLUSTER)
    Lachmann, Helen J.
    Lauwerys, Bernard
    Miettunen, Paivi
    Kallinich, Tilmann
    Horneff, Gerd
    Brik, Riva
    Manna, Rafaelle
    Murias, Sara
    Savic, Sinisa
    Smeets, Serge
    De Benedetti, Fabrizio
    Simon, Anna
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 207 - 208
  • [25] Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
    Bessette, Louis
    Joven-Ibanez, Beatriz
    Selmi, Carlo
    Chen, Naijun
    Kato, Koji
    Lippe, Ralph
    Zueger, Patrick
    Patel, Jayeshkumar
    Merola, Joseph
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 465 - 468
  • [26] Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis: Results from two phase 3 studies
    Strand, Vibeke
    de Vlam, Kurt
    Covarrubias-Cobos, Jose
    Mease, Philip
    Gladman, Dafna
    Hendrikx, Thijs
    Graham, Daniela
    Wu, Joseph
    Chen, Linda
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB109 - AB109
  • [27] EFFECT OF TOFACITINIB ON PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES
    Strand, V.
    de Vlam, K.
    Covarrubias-Cobos, J. A.
    Mease, P. J.
    Gladman, D. D.
    Hendrikx, T.
    Kudlacz, E.
    Graham, D.
    Wu, J.
    Chen, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1335 - 1336
  • [28] Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naive to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial
    Koschmieder, Steffen
    Isfort, Susanne
    Schulte, Clemens
    Jacobasch, Lutz
    Geer, Thomas
    Reiser, Marcel
    Koenigsmann, Michael
    Heinrich, Bernhard
    Wehmeyer, Jurgen
    von der Heyde, Eyck
    Tesch, Hans
    Groeschl, Benedikt
    Bachhuber, Petra
    Grosser, Susanne
    Pahl, Heike L.
    ANNALS OF HEMATOLOGY, 2023, 102 (12) : 3383 - 3399
  • [29] Improvements in Patient-Reported Outcomes After Treatment With Deucravacitinib in Patients With Psoriatic Arthritis: Results From a Randomized Phase 2 Trial
    Strand, Vibeke
    Gossec, Laure
    Coates, Laura C.
    Ogdie, Alexis
    Choi, Jiyoon
    Becker, Brandon
    Zhuo, Joe
    Lehman, Thomas
    Nowak, Miroslawa
    Elegbe, Ayanbola
    Mease, Philip J.
    Deodhar, Atul
    ARTHRITIS CARE & RESEARCH, 2024, 76 (08) : 1139 - 1148
  • [30] PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL
    Talpaz, M.
    Mascarenhas, J.
    Hoffman, R.
    Gerds, A. T.
    Stein, B.
    Gupta, V.
    Szoke, A.
    Drummond, M.
    Pristupa, A.
    Granston, T.
    Daly, R.
    Al-Fayoumi, S.
    Callahan, J. A.
    Singer, J. W.
    Gotlib, J.
    Jamieson, C.
    Harrison, C.
    Mesa, R.
    Verstovsek, S.
    HAEMATOLOGICA, 2017, 102 : 279 - 280
12345